<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03157128</url>
  </required_header>
  <id_info>
    <org_study_id>17477</org_study_id>
    <secondary_id>J2G-OX-JZJA</secondary_id>
    <secondary_id>LOXO-RET-17001</secondary_id>
    <secondary_id>2017-000800-59</secondary_id>
    <nct_id>NCT03157128</nct_id>
  </id_info>
  <brief_title>A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer</brief_title>
  <acronym>LIBRETTO-001</acronym>
  <official_title>A Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loxo Oncology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, first-in-human study designed to evaluate the safety, tolerability,&#xD;
      pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as&#xD;
      LOXO-292) administered orally to participants with advanced solid tumors, including&#xD;
      rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer&#xD;
      (MTC) and other tumors with RET activation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center Phase 1/2 study in participants with advanced solid&#xD;
      tumors, including RET fusion-positive solid tumors, MTC, and other tumors with RET&#xD;
      activation. The trial will be conducted in 2 parts: Phase 1 (dose escalation - completed) and&#xD;
      phase 2 (dose expansion). Participants with advanced cancer are eligible if they have&#xD;
      progressed on or are intolerant to available standard therapies, or no standard or available&#xD;
      curative therapy exists, or in the opinion of the Investigator, they would be unlikely to&#xD;
      tolerate or derive significant clinical benefit from appropriate standard of care therapy, or&#xD;
      they declined standard therapy. A dose of 160 milligrams (mg) twice a day (BID) has been&#xD;
      selected as the recommended phase 2 dose (RP2D). Approximately 950 participants with advanced&#xD;
      solid tumors harboring a RET gene alteration in tumor and/or blood will be enrolled to one of&#xD;
      seven phase 2 cohorts:&#xD;
&#xD;
        -  Cohort 1: Advanced RET fusion positive solid tumor for participants who progressed on or&#xD;
           intolerant to first line therapy (open)&#xD;
&#xD;
        -  Cohort 2: Advanced RET fusion positive solid tumor for treatment naïve participants&#xD;
           (open)&#xD;
&#xD;
        -  Cohort 3: Advanced RET-mutant MTC participants who progressed on or intolerant to first&#xD;
           line therapy (closed)&#xD;
&#xD;
        -  Cohort 4: Advanced RET-mutant MTC participants who are treatment naïve (closed)&#xD;
&#xD;
        -  Cohort 5: Advanced RET-altered solid tumor for participants otherwise ineligible for&#xD;
           cohorts 1-4. See details in inclusion/exclusion criteria (open)&#xD;
&#xD;
        -  Cohort 6: Participants otherwise eligible for Cohorts 1-5 who discontinued another RET&#xD;
           inhibitor due to intolerance may be eligible with prior Sponsor approval (open)&#xD;
&#xD;
        -  Cohort 7: RET fusion positive early-stage non-small cell lung cancer (NSCLC)&#xD;
           participants who are candidates for definitive surgery. Participants will receive&#xD;
           selpercatinib in a neoadjuvant and adjuvant setting. Participants will be followed for&#xD;
           disease recurrence for up to 5 years from the date of surgery (open in US only)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2017</start_date>
  <completion_date type="Anticipated">November 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 21, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: MTD</measure>
    <time_frame>The first 28 days of treatment (Cycle 1)</time_frame>
    <description>Incidence rate and category of dose limiting toxicities (DLTs) during the first 28-day cycle of LOXO-292 (selpercatinib) treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: RP2D</measure>
    <time_frame>The first 28 days of treatment (Cycle 1) and every cycle (28 days) for approximately 12 months (or earlier if the participant discontinues from the study)</time_frame>
    <description>Phase 1: RP2D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: Objective Response Rate</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, and 7 days after the last dose (for up to 2 years) in participants who have not progressed.</time_frame>
    <description>As assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Response Assessment in Neuro-Oncology (RANO), as appropriate to tumor type, as assessed by independent review committee (IRC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Number of Participants with a Treatment-Related Adverse Event(s) (TRAE[s])</measure>
    <time_frame>From the time of informed consent, for approximately 24 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose)</time_frame>
    <description>Phase 1: Number of Participants with a TRAE(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Number of Participants with an Abnormal Laboratory or Physical Exam Result(s)</measure>
    <time_frame>From the time of informed consent, for approximately 24 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose)</time_frame>
    <description>Phase 1: Number of Participants with an Abnormal Laboratory or Physical Exam Result(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Overall Response Rate (ORR) based on RECIST 1.1 or RANO, as Appropriate to Tumor Type</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 1: ORR based on RECIST 1.1 or RANO, as Appropriate to Tumor Type</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: ORR (by Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 2: ORR (by Investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 2: Best Change in Tumor Size from Baseline (by IRC and Investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Duration of Response (DOR; by IRC and Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 2: DOR (by IRC and Investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Central Nervous System (CNS) ORR (by IRC)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 2: CNS ORR (by IRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: CNS DOR (by IRC)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 2: CNS DOR (by IRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Time to Any and Best Response (by IRC and Investigator)</measure>
    <time_frame>every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 2: Time to Any and Best Response (by IRC and Investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: CBR (by IRC and Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 2: CBR (by IRC and Investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: PFS (by IRC and Investigator)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 2: PFS (by IRC and Investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Overall Survival (OS)</measure>
    <time_frame>Approximately every 8 weeks for one year, then every 12 weeks, 7 days after the last dose (for up to 2 years) in participants who have not progressed</time_frame>
    <description>Phase 2: OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: Percentage of Participants with any Serious Adverse Event (SAE[s])</measure>
    <time_frame>From the time of informed consent, for approximately 24 months (or earlier if the participant discontinues from the study), and through Safety Follow-up (28 days after the last dose)</time_frame>
    <description>Phase 2: Percentage of Participants with any SAE(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Pharmacokinetics (PK): Area Under the Plasma Concentration-Time Curve of LOXO-292 (Selpercatinib)</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 5 Day 1 (Cycle = 28 days)</time_frame>
    <description>Phase 1 and 2: PK: AUC of LOXO-292 (Selpercatinib)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: PK: Maximum Concentration (Cmax) of LOXO-292 (Selpercatinib)</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 5 Day 1 (Cycle = 28 days)</time_frame>
    <description>Phase 1 and 2: PK: Cmax of LOXO-292 (Selpercatinib)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">989</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Medullary Thyroid Cancer</condition>
  <condition>Colon Cancer</condition>
  <condition>Any Solid Tumor</condition>
  <arm_group>
    <arm_group_label>LOXO-292</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1 - Multiple doses of LOXO-292 (selpercatinib) Phase 2 - The maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOXO-292</intervention_name>
    <description>Oral LOXO-292</description>
    <arm_group_label>LOXO-292</arm_group_label>
    <other_name>Selpercatinib</other_name>
    <other_name>LY3527723</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        For Phase 1:&#xD;
&#xD;
          -  Participants with a locally advanced or metastatic solid tumor that:&#xD;
&#xD;
          -  Has progressed on or is intolerant to standard therapy, or&#xD;
&#xD;
          -  For which no standard therapy exists, or in the opinion of the Investigator, are not&#xD;
             candidates for or would be unlikely to tolerate or derive significant clinical benefit&#xD;
             from standard therapy, or&#xD;
&#xD;
          -  Decline standard therapy&#xD;
&#xD;
          -  Prior multikinase inhibitors (MKIs) with anti-RET activity are allowed&#xD;
&#xD;
          -  A RET gene alteration is not required initially. Once adequate PK exposure is&#xD;
             achieved, evidence of RET gene alteration in tumor and/or blood is required as&#xD;
             identified through molecular assays, as performed for clinical evaluation&#xD;
&#xD;
          -  Measurable or non-measurable disease as determined by RECIST 1.1 or RANO as&#xD;
             appropriate to tumor type&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2 or Lansky Performance&#xD;
             Score (LPS) greater than or equal to (≥) 40 percent (%) (age less than [&lt;] 16 years)&#xD;
             with no sudden deterioration 2 weeks prior to the first dose of study treatment&#xD;
&#xD;
          -  Adequate hematologic, hepatic and renal function&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
        For Phase 2: As for phase 1 with the following modifications:&#xD;
&#xD;
          -  For Cohort 1: Participants must have received prior standard therapy appropriate for&#xD;
             their tumor type and stage of disease, or in the opinion of the Investigator, would be&#xD;
             unlikely to tolerate or derive clinical benefit from appropriate standard of care&#xD;
             therapy&#xD;
&#xD;
          -  Cohorts 1 and 2:&#xD;
&#xD;
               -  Enrollment will be restricted to participants with evidence of a RET gene&#xD;
                  alteration in tumor&#xD;
&#xD;
               -  At least one measurable lesion as defined by RECIST 1.1 or RANO, as appropriate&#xD;
                  to tumor type and not previously irradiated&#xD;
&#xD;
          -  Cohorts 3 and 4: Enrollment closed&#xD;
&#xD;
          -  Cohort 5:&#xD;
&#xD;
               -  Without measurable disease but otherwise meet criteria for Cohorts 1 and 2;&#xD;
&#xD;
               -  MTC syndrome spectrum cancers (e.g., MTC, pheochromocytoma), cancers with&#xD;
                  neuroendocrine features/differentiation, or poorly differentiated thyroid cancers&#xD;
                  with other RET alteration/activation may be allowed with prior Sponsor approval;&#xD;
&#xD;
               -  cfDNA positive for a RET gene alteration not known to be present in a tumor&#xD;
                  sample&#xD;
&#xD;
          -  Cohort 6: Participants who otherwise are eligible for Cohorts 1, 2 or 5 who&#xD;
             discontinued another RET inhibitor due to intolerance may be eligible with prior&#xD;
             Sponsor approval&#xD;
&#xD;
          -  Cohort 7: Participants must have a histologically confirmed stage IB-IIIA NSCLC by&#xD;
             AJCC (The American Joint Committee on Cancer) version 8. The tumor must have been&#xD;
             deemed resectable by a thoracic surgeon, the participant must be determined to be&#xD;
             medically operable based on the determination of a thoracic surgeon, and the&#xD;
             participant must not have received prior systemic therapy, including prior radiation&#xD;
             therapy, for NSCLC.&#xD;
&#xD;
        Key Exclusion Criteria (Phase 1 and Phase 2):&#xD;
&#xD;
          -  Phase 2 Cohorts 1 and 2: an additional known oncogenic driver&#xD;
&#xD;
          -  Cohorts 3 and 4: Enrollment closed&#xD;
&#xD;
          -  Cohorts 1, 2 and 5: prior treatment with a selective RET inhibitor Notes: Participants&#xD;
             otherwise eligible for Cohorts 1, 2, and 5 who discontinued another selective RET&#xD;
             inhibitor may be eligible for Phase 2 Cohort 6 with prior Sponsor approval&#xD;
&#xD;
          -  Investigational agent or anticancer therapy (including chemotherapy, biologic therapy,&#xD;
             immunotherapy, anticancer Chinese medicine or other anticancer herbal remedy) within 5&#xD;
             half-lives or 2 weeks (whichever is shorter) prior to planned start of LOXO-292&#xD;
             (selpercatinib). In addition, no concurrent investigational anti-cancer therapy is&#xD;
             permitted Note: Potential exception for this exclusion criterion will require a valid&#xD;
             scientific justification and approval from the Sponsor&#xD;
&#xD;
          -  Major surgery (excluding placement of vascular access) within 4 weeks prior to planned&#xD;
             start of LOXO-292 (selpercatinib)&#xD;
&#xD;
          -  Radiotherapy with a limited field of radiation for palliation within 1 week of planned&#xD;
             start of LOXO-292 (selpercatinib), with the exception of participants receiving&#xD;
             radiation to more than 30% of the bone marrow or with a wide field of radiation, which&#xD;
             must be completed at least 4 weeks prior to the first dose of study treatment&#xD;
&#xD;
          -  Any unresolved toxicities from prior therapy greater than Common Terminology Criteria&#xD;
             for Adverse Events (CTCAE) Grade 1 at the time of starting study treatment with the&#xD;
             exception of alopecia and Grade 2, prior platinum-therapy related neuropathy&#xD;
&#xD;
          -  Symptomatic primary CNS tumor, metastases, leptomeningeal carcinomatosis, or untreated&#xD;
             spinal cord compression. Participants are eligible if neurological symptoms and CNS&#xD;
             imaging are stable and steroid dose is stable for 14 days prior to the first dose of&#xD;
             LOXO-292 (selpercatinib) and no CNS surgery or radiation has been performed for 28&#xD;
             days, 14 days if stereotactic radiosurgery (SRS)&#xD;
&#xD;
          -  Clinically significant active cardiovascular disease or history of myocardial&#xD;
             infarction within 6 months prior to planned start of LOXO-292 (selpercatinib) or&#xD;
             prolongation of the QT interval corrected (QTcF) greater than (&gt;) 470 milliseconds&#xD;
             (msec)&#xD;
&#xD;
          -  Required treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or&#xD;
             inducers and certain prohibited concomitant medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic of Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>480-301-8000</phone>
    </contact>
    <investigator>
      <last_name>Nina J Karlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-0269</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>818-359-8111</phone>
    </contact>
    <investigator>
      <last_name>Erminia Massarelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California - San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-822-6189</phone>
    </contact>
    <investigator>
      <last_name>Lyudmila Bazhenova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-794-1816</phone>
    </contact>
    <investigator>
      <last_name>Jonathan W Goldman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hoag Memoriall Hospital Presbyterian</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>949-761-6767</phone>
    </contact>
    <investigator>
      <last_name>Michael Demeure</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-456-8105</phone>
    </contact>
    <investigator>
      <last_name>Viola W Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center at Mission Bay</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-885-3882</phone>
    </contact>
    <investigator>
      <last_name>Hyunseok Kang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Santa Clara</city>
        <state>California</state>
        <zip>95051</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>708-851-9588</phone>
    </contact>
    <investigator>
      <last_name>Minggui Pan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>510-891-3414</phone>
    </contact>
    <investigator>
      <last_name>Jennifer M. Suga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute at HealthOne</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>720-754-2610</phone>
    </contact>
    <investigator>
      <last_name>Gerald S Falchook</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-737-5234</phone>
    </contact>
    <investigator>
      <last_name>Frederick H Wilson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>202-660-6500</phone>
    </contact>
    <investigator>
      <last_name>Benjamin Levy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic-Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>904-953-2224</phone>
    </contact>
    <investigator>
      <last_name>Victor Bernet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital Pembroke</name>
      <address>
        <city>Pembroke</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-265-4325</phone>
    </contact>
    <investigator>
      <last_name>Luis Raez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-778-5378</phone>
    </contact>
    <investigator>
      <last_name>Conor Steuer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medicine-Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christine M Bestvina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>504-842-3910</phone>
    </contact>
    <investigator>
      <last_name>Marc R Matrana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>410-328-8708</phone>
    </contact>
    <investigator>
      <last_name>Christian Rolfo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-726-2000</phone>
    </contact>
    <investigator>
      <last_name>Lori Wirth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-632-2307</phone>
    </contact>
    <investigator>
      <last_name>Jacob Sands</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>734-764-1817</phone>
    </contact>
    <investigator>
      <last_name>Francis Worden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>START Midwest</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>616-954-5554</phone>
    </contact>
    <investigator>
      <last_name>Nehal Lakhani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>507-284-4080</phone>
    </contact>
    <investigator>
      <last_name>John Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University Medical School</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-362-7229</phone>
    </contact>
    <investigator>
      <last_name>Saiama N Waqar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>702-952-3400</phone>
    </contact>
    <investigator>
      <last_name>Fadi S Braiteh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>716-845-3099</phone>
    </contact>
    <investigator>
      <last_name>Grace Dy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>212-731-5662</phone>
    </contact>
    <investigator>
      <last_name>Vamsidhar Velcheti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>646-888-4206</phone>
    </contact>
    <investigator>
      <last_name>Alexander Drilon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>866-869-1856</phone>
    </contact>
    <investigator>
      <last_name>Jared Weiss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>216-444-1128</phone>
    </contact>
    <investigator>
      <last_name>Nathan Pennell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>614-293-4680</phone>
    </contact>
    <investigator>
      <last_name>Manisha H Shah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-494-8534</phone>
    </contact>
    <investigator>
      <last_name>Kyaw Z Thein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-746-6344</phone>
    </contact>
    <investigator>
      <last_name>Devraj Basu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jennifer M Johnson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute SCRI</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-329-7274</phone>
    </contact>
    <investigator>
      <last_name>Todd M Bauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6307</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>6159368580</phone>
    </contact>
    <investigator>
      <last_name>Jordan David Berlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-648-4180</phone>
    </contact>
    <investigator>
      <last_name>Beg Muhammad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>713-745-6754</phone>
    </contact>
    <investigator>
      <last_name>Vivek Subbiah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>801-585-5986</phone>
    </contact>
    <investigator>
      <last_name>Wallace L Akerley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>703-280-5390</phone>
    </contact>
    <investigator>
      <last_name>Alexander I Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison Hospital and Health Clinic</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>608-262-2803</phone>
    </contact>
    <investigator>
      <last_name>Mark Burkard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61299267267</phone>
    </contact>
    <investigator>
      <last_name>Bruce Robinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>61385595000</phone>
    </contact>
    <investigator>
      <last_name>Benjamin Solomon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>6048776000</phone>
    </contact>
    <investigator>
      <last_name>Janessa Laskin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <state>København Ø</state>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>004535456353</phone>
    </contact>
    <investigator>
      <last_name>Kristoffer Rohrberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <state>Cedex 15</state>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33156093714</phone>
    </contact>
    <investigator>
      <last_name>Jacques Medioni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>556333244</phone>
    </contact>
    <investigator>
      <last_name>Antoine Italiano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex 08</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33426556833</phone>
    </contact>
    <investigator>
      <last_name>Philippe Cassier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33491385918</phone>
    </contact>
    <investigator>
      <last_name>Pascale Tomasini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier - Val d'aurelle</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>33467613100</phone>
    </contact>
    <investigator>
      <last_name>Diego Tosi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>33142114157</phone>
    </contact>
    <investigator>
      <last_name>Benjamin Besse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg A. ö. R.</name>
      <address>
        <city>Würzburg</city>
        <state>Bayern</state>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>4993120139939</phone>
    </contact>
    <investigator>
      <last_name>Barbara Deschler-Baier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Köln</name>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>492214783993</phone>
    </contact>
    <investigator>
      <last_name>Jürgen Wolf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Shatin, New Territories</state>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>85226322648</phone>
    </contact>
    <investigator>
      <last_name>Herbert Ho Fung Loong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <state>Ramat Gan</state>
        <zip>5265601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972526667591</phone>
    </contact>
    <investigator>
      <last_name>Talia Golan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Soroka Medical Center - Pediatric Outpatient Clinic</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972587040620</phone>
    </contact>
    <investigator>
      <last_name>Julia Dudnik</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>972508946057</phone>
    </contact>
    <investigator>
      <last_name>Hovav Nechushtan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <state>Lombardie</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>390223902906</phone>
    </contact>
    <investigator>
      <last_name>Filippo De Braud</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81527412111</phone>
    </contact>
    <investigator>
      <last_name>Masahiro Morise</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81471331111</phone>
    </contact>
    <investigator>
      <last_name>Koichi Goto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8648</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81 117161161</phone>
    </contact>
    <investigator>
      <last_name>Jun Sakakibara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hyogo Cancer Center</name>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81789291151</phone>
    </contact>
    <investigator>
      <last_name>Miyako Satouchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanazawa University Hospital</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81762652000</phone>
    </contact>
    <investigator>
      <last_name>Shinji Takeuchi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osaka Sayama-shi</city>
        <state>Osaka</state>
        <zip>589 8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81723660221</phone>
    </contact>
    <investigator>
      <last_name>Tsutomu Iwasa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Nagaizumi</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81559895222</phone>
    </contact>
    <investigator>
      <last_name>Hirotsugu Kenmotsu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81335422511</phone>
    </contact>
    <investigator>
      <last_name>YUICHIRO OHE</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Japanese Foundation for Cancer Research</name>
      <address>
        <city>Koto</city>
        <state>Tokyo</state>
        <zip>135-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81335200111</phone>
    </contact>
    <investigator>
      <last_name>Makoto Nishio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tottori University Hospital</name>
      <address>
        <city>Yonago</city>
        <state>Tottori</state>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81859331111</phone>
    </contact>
    <investigator>
      <last_name>Tomohiro Sakamoto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyushu Cancer Center</name>
      <address>
        <city>Fukuoka</city>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81925413231</phone>
    </contact>
    <investigator>
      <last_name>Ryo Toyozawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81862357226</phone>
    </contact>
    <investigator>
      <last_name>Kadoaki Ohashi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka City General Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>81669291221</phone>
    </contact>
    <investigator>
      <last_name>Haruko Daga</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82319201154</phone>
    </contact>
    <investigator>
      <last_name>Ji-Youn Han</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Kyǒnggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82317877005</phone>
    </contact>
    <investigator>
      <last_name>Yu Jung Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8222243214</phone>
    </contact>
    <investigator>
      <last_name>Dae Ho Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi [Seoul]</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82234101132</phone>
    </contact>
    <investigator>
      <last_name>Se Hoon Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>82222280880</phone>
    </contact>
    <investigator>
      <last_name>Byoung Chul Cho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>6564368000</phone>
    </contact>
    <investigator>
      <last_name>Shao Weng Daniel Tan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>934893000</phone>
    </contact>
    <investigator>
      <last_name>Elena Garralda Cabanas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>34915504800</phone>
    </contact>
    <investigator>
      <last_name>Victor Moreno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Norte Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>917567800</phone>
    </contact>
    <investigator>
      <last_name>Valentina Boni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern 16</city>
        <state>Luzern</state>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0041412056849</phone>
    </contact>
    <investigator>
      <last_name>Oliver Gautschi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705, ROC</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>886423592525</phone>
    </contact>
    <investigator>
      <last_name>Kuo-Hsuan Hsu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>8862231245665339</phone>
    </contact>
    <investigator>
      <last_name>Chih-Hsin Yang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>02086426011</phone>
    </contact>
    <investigator>
      <last_name>Anna Minchom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 9, 2017</study_first_submitted>
  <study_first_submitted_qc>May 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2017</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LOXO-292</keyword>
  <keyword>KIF5B-RET</keyword>
  <keyword>M918T</keyword>
  <keyword>CCDC6-RET</keyword>
  <keyword>RET-PTC1</keyword>
  <keyword>NCOA4-RET</keyword>
  <keyword>RET-PTC</keyword>
  <keyword>RET-PTC3</keyword>
  <keyword>RET-PTC4</keyword>
  <keyword>PRKAR1A-RET</keyword>
  <keyword>RET-PTC2</keyword>
  <keyword>GOLGA5-RET</keyword>
  <keyword>RET-PTC5</keyword>
  <keyword>ERC1-RET</keyword>
  <keyword>KTN1-RET</keyword>
  <keyword>RET-PTC8</keyword>
  <keyword>HOOK3-RET</keyword>
  <keyword>PCM1-RET</keyword>
  <keyword>TRIM24-RET</keyword>
  <keyword>RET-PTC6</keyword>
  <keyword>TRIM27-RET</keyword>
  <keyword>TRIM33-RET</keyword>
  <keyword>RET-PTC7</keyword>
  <keyword>AKAP13-RET</keyword>
  <keyword>FKBP15-RET</keyword>
  <keyword>SPECC1L-RET</keyword>
  <keyword>TBL1XR1-RET</keyword>
  <keyword>BCR-RET</keyword>
  <keyword>FGRF1OP-RET</keyword>
  <keyword>RFG8-RET</keyword>
  <keyword>RET-PTC9</keyword>
  <keyword>ACBD5-RET</keyword>
  <keyword>MYH13-RET</keyword>
  <keyword>CUX1-RET</keyword>
  <keyword>KIAA1468-RET</keyword>
  <keyword>FRMD4A-RET</keyword>
  <keyword>SQSTM1-RET</keyword>
  <keyword>AFAP1L2-RET</keyword>
  <keyword>PPFIBP2-RET</keyword>
  <keyword>EML4-RET</keyword>
  <keyword>PARD3-RET</keyword>
  <keyword>G533C</keyword>
  <keyword>C609F</keyword>
  <keyword>C609G</keyword>
  <keyword>C609R</keyword>
  <keyword>C609S</keyword>
  <keyword>C609Y</keyword>
  <keyword>C611F</keyword>
  <keyword>C611G</keyword>
  <keyword>C611S</keyword>
  <keyword>C611Y</keyword>
  <keyword>C611W</keyword>
  <keyword>C618F</keyword>
  <keyword>C618R</keyword>
  <keyword>C618S</keyword>
  <keyword>C620F</keyword>
  <keyword>C620R</keyword>
  <keyword>C620S</keyword>
  <keyword>C630R</keyword>
  <keyword>C630Y</keyword>
  <keyword>D631Y</keyword>
  <keyword>C634F</keyword>
  <keyword>C634G</keyword>
  <keyword>C634R</keyword>
  <keyword>C634S</keyword>
  <keyword>C634W</keyword>
  <keyword>C634Y</keyword>
  <keyword>K666E</keyword>
  <keyword>E768D</keyword>
  <keyword>L790F</keyword>
  <keyword>V804L</keyword>
  <keyword>V804M</keyword>
  <keyword>A883F</keyword>
  <keyword>S891A</keyword>
  <keyword>R912P</keyword>
  <keyword>CLIP1-RET</keyword>
  <keyword>Y806C</keyword>
  <keyword>RET fusion</keyword>
  <keyword>RET alteration</keyword>
  <keyword>RET mutation</keyword>
  <keyword>RET rearrangement</keyword>
  <keyword>RET translocation</keyword>
  <keyword>Neoplasms by Site</keyword>
  <keyword>Neoplasms</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Lung Neoplasms</keyword>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <keyword>Cancer of Lung</keyword>
  <keyword>Cancer of the Lung</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Neoplasms, Lung</keyword>
  <keyword>Neoplasms, Pulmonary</keyword>
  <keyword>Pulmonary Cancer</keyword>
  <keyword>Pulmonary Neoplasms</keyword>
  <keyword>Respiratory Tract Neoplasms</keyword>
  <keyword>Lung Diseases</keyword>
  <keyword>Respiratory Tract Diseases</keyword>
  <keyword>Carcinoma, Bronchogenic</keyword>
  <keyword>Bronchial Neoplasms</keyword>
  <keyword>Medullary Thyroid Cancer</keyword>
  <keyword>Papillary Thyroid Cancer</keyword>
  <keyword>Thyroid Diseases</keyword>
  <keyword>Thyroid Neoplasms</keyword>
  <keyword>Cancer of the Thyroid</keyword>
  <keyword>Cancer of Thyroid</keyword>
  <keyword>Neoplasms, Thyroid</keyword>
  <keyword>Thyroid Ademona</keyword>
  <keyword>Thyroid Cancer</keyword>
  <keyword>Thyroid Carcinoma</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Endocrine Gland Neoplasms</keyword>
  <keyword>Head and Neck Neoplasms</keyword>
  <keyword>Thoracic Neoplasms</keyword>
  <keyword>CNS tumor</keyword>
  <keyword>Primary CNS tumor</keyword>
  <keyword>Cancer of Colon</keyword>
  <keyword>Cancer of the Colon</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Colon Neoplasms</keyword>
  <keyword>Colonic Cancer</keyword>
  <keyword>Neoplasms, Colonic</keyword>
  <keyword>Malignant tumor of Breast</keyword>
  <keyword>Mammary Cancer</keyword>
  <keyword>Mammary Carcinoma, Human</keyword>
  <keyword>Mammary Neoplasm, Human</keyword>
  <keyword>Neoplasms, Breast</keyword>
  <keyword>Tumors, Breast</keyword>
  <keyword>Human Mammary Carcinoma</keyword>
  <keyword>Malignant Neoplasm of Breast</keyword>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Breast Tumors</keyword>
  <keyword>Cancer of the Breast</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>RET Inhibitor</keyword>
  <keyword>MTC</keyword>
  <keyword>NSCLC</keyword>
  <keyword>selpercatinib</keyword>
  <keyword>neo-adjuvant treatment in early stage NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

